Shenzhen Antai Weisheng Medicine

Shenzhen Antai Weisheng Medicine is a clinical-stage biopharmaceutical company focused on developing breakthrough treatments for chronic infectious diseases, particularly Hepatitis B. The company was founded by Dr. Zhang Xumu, a distinguished professor and expert in asymmetric catalysis, which provides a strong chemical synthesis foundation for their drug discovery efforts. Their lead candidate, ATW-111, is a novel capsid assembly modulator (CAM) currently in clinical trials, designed to disrupt the HBV life cycle and contribute to a functional cure. Antaiweisheng aims to address significant unmet medical needs in the antiviral space through its proprietary R&D platform and strategic collaborations. The company is headquartered in Shenzhen's high-tech industrial zone and has received backing from leading Chinese venture capital investors. By leveraging advanced medicinal chemistry, the company continues to expand its pipeline to include therapies for other viral infections.